Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory industry lobbying

European Drugmakers Urge EU Pharma Investment

Analysis based on 9 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026

Sentiment
-10
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The letter is a lobbying appeal rather than a binding policy change, so near-term market impact is limited, though it highlights structural competitive pressure on European pharmaceutical capital allocation and could influence future EU healthcare spending and regulatory debates. If EU policymakers respond with faster trial approvals and higher medicine spending, European drugmakers could see improved research pipelines and revenue prospects, while continued inaction would reinforce the relative advantage of US and Chinese competitors.

pharmaceuticals healthcare biotechnology

Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry. The signatories were AstraZeneca, GSK plc, Novo Nordisk, Novartis, Roche, Sanofi, Boehringer Ingelheim, Chiesi Farmaceutici and Ipsen. The letter urges faster clinical trials, stronger intellectual property protections and greater fiscal flexibility on healthcare spending, warning that without urgent action strategic sectors such as pharmaceuticals face a slow agony of decline. The chairs stated that roughly 40% of new therapies never reach European patients, that the bloc's share of global drug research and development has fallen to 31% from 43% in 1990, and that its share of commercial clinical trials has halved to 9% over the past decade. They noted Europe spends about 1% of GDP on pharmaceuticals, versus 2% in the United States and 1.8% in China. Amsterdam-based healthcare lawyer Ron Lanton said Europe retains extraordinary scientific capabilities but companies increasingly plan around more aggressive US policies, weighing the entire pathway from clinical trials to reimbursement and patient access when deciding where to allocate capital. The appeal reflects boardroom frustration with European systems and policies that move more slowly than those in the United States and China, which attract billions of dollars more in pharmaceutical investment.

70 AstraZeneca signed open letter European Union
70 GSK plc signed open letter European Union
70 Novo Nordisk signed open letter European Union
70 Novartis signed open letter European Union
70 Roche signed open letter European Union
70 Sanofi signed open letter European Union
60 Boehringer Ingelheim signed open letter European Union
60 Chiesi Farmaceutici signed open letter European Union
60 Ipsen signed open letter European Union
alliance
The primary target of the open letter, which asks the bloc and its member states to boost pharmaceutical investment, speed up trials and provide fiscal flexibility on healthcare spending. How the European Union responds could shape the region's drug industry competitiveness.
Importance 85.0 Sentiment 0.0
stock
One of the nine signatories of the open letter urging the European Union to boost pharmaceutical investment and speed up trials. The appeal signals concern over European competitiveness but does not change its near-term financial outlook.
Importance 70.0 Sentiment 5.0
stock
A signatory of the open letter pressing the European Union for more medicine spending, faster trials and IP protection. Its participation underscores the sector's push for a more favorable European operating environment.
Importance 70.0 Sentiment 5.0
stock
One of the nine drugmakers signing the letter calling for greater EU investment in pharmaceuticals. The initiative reflects its interest in faster European clinical trials and improved market access.
Importance 70.0 Sentiment 5.0
stock
A signatory of the open letter urging the European Union and member states to strengthen the region's pharmaceutical industry. The appeal is aimed at improving the investment and regulatory climate it operates in.
Importance 70.0 Sentiment 5.0
stock
One of the nine companies whose chairs signed the letter seeking faster trials, IP protections and fiscal flexibility in Europe. The move highlights its stake in European research and development competitiveness.
Importance 70.0 Sentiment 5.0
stock
A signatory of the open letter calling on the European Union to boost pharmaceutical investment. The appeal reflects its concern about Europe lagging the United States and China in drug research and trials.
Importance 70.0 Sentiment 5.0
priv
One of the nine signatories of the open letter urging EU action on medicine spending, trials and IP protection. Its participation signals shared industry concern over European competitiveness.
Importance 60.0 Sentiment 5.0
priv
A signatory of the open letter pressing the European Union to improve conditions for pharmaceutical investment. The appeal is part of a broader industry push for faster European trials and market access.
Importance 60.0 Sentiment 5.0
stock
One of the nine drugmakers signing the letter calling for greater EU investment in the sector. The initiative reflects its interest in a more competitive European pharmaceutical environment.
Importance 60.0 Sentiment 5.0
cnt
Cited as a key competitor attracting far more pharmaceutical investment, with healthcare spending at about 2% of GDP versus Europe's 1%. Its more aggressive policies are said to be drawing capital and launches away from Europe.
Importance 40.0 Sentiment 0.0
cnt
Named alongside the United States as a rival attracting billions more in pharmaceutical investment, with spending at about 1.8% of GDP. Its rise adds pressure on Europe to reform its drug industry policies.
Importance 40.0 Sentiment 0.0
European Union related ↔ Roche
European Union related ↔ Sanofi
AstraZeneca related ↔ Novartis
AstraZeneca related ↔ Roche
AstraZeneca related ↔ Sanofi
Novo Nordisk related ↔ Roche
Novo Nordisk related ↔ Sanofi
Novartis related ↔ Roche
Novartis related ↔ Sanofi
Roche related ↔ Sanofi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.